ClinicalTrials.gg
Active, not recruitingNCT05895305Updated Dec 15, 2025

Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Airway Stenosis

An Early Phase 1 interventional study of Paclitaxel-Coated Pulmonary Balloon Catheter in Central Airway Obstruction, sponsored by Airiver Medical, Inc.. Active, not recruiting at 1 site in Georgia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Airiver Medical, Inc. · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this Prospective Trial of Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Airway Obstruction (OXYGEN-1) is to evaluate clinical safety and potential efficacy of the Airiver Pulmonary DCB in the treatment of benign central airway stenosis.

Read the detailed description

Benign central airway stenosis/obstruction, including stenosis of the subglottic area, trachea, and bronchi, is related to significant morbidity due to dyspnea and impaired quality of life. It is hypothesized that Airiver pulmonary drug-coated balloon (DCB) will improve patient outcome in the bronchoscopic treatment of benign airway obstruction, and, as an adjunct to standard of care, will prolong airway patency compared to the standard of care alone. This is a prospective, multi-center, single-arm, open-label, safety \& feasibility, OUS first in human study for safety and potential efficacy.

02

Conditions studied

  • Central Airway Obstruction

Browse trials for

Keywords

  • benign
  • central airway obstruction
  • drug coated balloon
03

In context

Airway Obstruction

148 studies on the registry are indexed under Airway Obstruction; 26 are open to participants now.

This study's enrollment of 45 is below the median of 52 across 93 interventional studies indexed under Airway Obstruction.

Browse Airway Obstruction studies →

Lead sponsor

Airiver Medical, Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged ≥18 old
  4. Symptomatic, severe (> 50%) benign CAO (by CT or bronchoscopy)

    1. Stenosis is distal to cricoid and proximal to segmental bronchi
    2. Indicated for balloon dilation only or as an adjunct to standard of care
    3. Includes, but not limited to :

      • Post intubation tracheal stenosis (PITS)
      • Post tracheostomy tracheal stenosis (PTTS)
      • Post lung transplantation stenosis
      • Stenosis related to airway stent
      • Subglottic stenosis (SGS)
      • Stenosis due to tuberculosis

Exclusion criteria

Exclusion Criteria:

  1. Malignant CAO
  2. Dynamic etiology of benign stenosis such as excessive dynamic airway collapse, tracheobronchomalacia, or stenosis due to external compression
  3. Presence of a known perforation at the site of proposed dilation
  4. Presence of a known fistula between the tracheobronchial tree and esophagus, mediastinum to pleural space
  5. Obstruction not amenable to bronchoscopic dilation in the opinion of the investigator
  6. Allergy to paclitaxel or structurally related compounds
  7. Severe coagulation disorders or current use of anticoagulant or antiplatelet medication that cannot be safely managed per recommended guidelines prior to the index procedure
  8. Acute stricture condition that requires emergent procedure (e.g., immediate dilation)
  9. Vasculitis that is not well controlled
  10. Inability to tolerate bronchoscopy or to bronchoscopy, anesthesia, or deep sedation
  11. Any anatomical limitation of the head and neck, oral cavity or laryngopharynx that may preclude bronchoscopic evaluation or treatment
  12. Patient with active pulmonary infection, including but not limited to: COVID-19, influenza, etc.
  13. Any disease or condition that interferes with safe completion of the study, such as severe or severe asthma or pulmonary fibrosis.
  14. Patients actively being treated with therapy or with an active immunosuppressed state due to other treatment or underlying disease.
  15. Pregnancy or planning on pregnant during the first 12 months of enrollment in the study
  16. \<1 year
  17. Patient is currently enrolled in other studies. Participation in studies for products approved in the US are not considered investigational
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Single arm treated by Airiver Pulmonary DCB

    subject will be treated by Airiver Pulmonary Drug Coated Balloon (DCB) catheter. The balloon is coated with a paclitaxel drug (3.5ug/mm2).

    Combination Product: Paclitaxel-Coated Pulmonary Balloon Catheter

Interventions

  • Combination productPaclitaxel-Coated Pulmonary Balloon Catheter

    Subjects with benign airway stenosis will be treated by Airiver pulmonary DCB at index procedure

    Also known as: DCB

06

What researchers measure

Primary outcomes

  1. Primary safety: Freedom from major adverse device events (MADE) post index procedure through 30 days.

    MADE is defined as: * Airway perforation (Pneumothorax) * Pneumomediastinum * Massive bleeding * Mediastinitis requiring the need for IV antibiotics and / or hospitalization * Respiratory distress or asphyxia requiring intubation or reintervention * Evidence of negative local tissue reaction to paclitaxel Subjects failing any component of the primary safety endpoint will be considered a safety failure, and subjects who remain event free through 30 days will be considered safety successes. Primary safety will be assessed as the proportion of subjects free from the primary safety event.

    Time frame: 30 days

  2. Primary efficacy: Freedom from symptom-driven target lesion reintervention (TLR) due to recurrence of stenosis through 6 months

    The incidence of subjects free from symptom-driven TLR will be assessed via Kaplan-Meier survival analysis.

    Time frame: 6 months

Secondary outcomes

  1. Incidence of, and time to, symptom-driven target lesion reintervention through 12 months.

    assessed via Kaplan-Meier survival analysis.

    Time frame: 12 months

  2. Bronchoscopic target lesion patency (Myer-Cotton airway grading system) change through 12 months.

    Grade 1 - 0-50% obstruction Grade 2 - 51-70% obstruction Grade 3 - 71-99% obstruction Grade 4 - No detectable lumen.

    Time frame: 12 months

  3. Spirometry (FEV1) change through 12 months

    A spirometry will be compared at baseline vs follow-ups. Lower readings indicate more significant obstruction.

    Time frame: 12 months

  4. mMRC (Modified Medical Research Council) dyspnea scale change through 12 months

    The grade range is from 0-4. Higher grades indicate worse respiratory disability.

    Time frame: 12 months.

  5. Quality of life (QOL) change: Patient report outcomes (SF-12) through 12 months

    Converting SF-12 Item Responses to Physical and Mental Standardized Values. Higher scores indicate better health

    Time frame: 12 months

  6. Clinical pharmacokinetics of paclitaxel by 10 days

    plasma paclitaxel concentration will be assessed per predesignated time points.

    Time frame: 10 days

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Oct 2025, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 8, 2023
StartActual
May 16, 2023
Primary completionActual
Oct 4, 2025
CompletionEst.
Oct 4, 2029
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05895305
Lead sponsor
Airiver Medical, Inc.
Collaborators
Libra Medical
Responsible party
Sponsor
First posted
Jun 8, 2023
Start date
May 16, 2023
Primary completion
Oct 4, 2025
Completion
Oct 4, 2029 (estimated)
Last update
Dec 15, 2025

Study contacts

Kakha Vacharadze, MD
principal investigator · National Center for Tuberculosis and Lung Diseases, Tbilisi State Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion